Al Abo M, Foo W, Howard L, McGue S, Lacroix B, Kephart J
NPJ Precis Oncol. 2025; 9(1):30.
PMID: 39880920
PMC: 11779911.
DOI: 10.1038/s41698-025-00817-9.
Chatterjee A, Fan X, Slear J, Asare G, Yousuf A, Medved M
Cancers (Basel). 2024; 16(20).
PMID: 39456593
PMC: 11505680.
DOI: 10.3390/cancers16203499.
Dee E, Todd R, Ng K, Aidoo-Micah G, Amen T, Moon Z
Nat Rev Urol. 2024; .
PMID: 39424981
DOI: 10.1038/s41585-024-00948-x.
Sundaresan V, Lokeshwar S, Sutherland R, Sohoni N, Golos A, Ajjawi I
Abdom Radiol (NY). 2024; .
PMID: 39325212
DOI: 10.1007/s00261-024-04603-2.
Ramakrishnan S, Cortes-Gomez E, Athans S, Attwood K, Rosario S, Kim S
Genome Med. 2024; 16(1):52.
PMID: 38566104
PMC: 10988846.
DOI: 10.1186/s13073-024-01323-6.
MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer.
Khan M, Acharya S, Anand S, Sameeta F, Pramanik P, Keel C
iScience. 2023; 26(12):108487.
PMID: 38089573
PMC: 10711386.
DOI: 10.1016/j.isci.2023.108487.
Development and validation of two nomograms for predicting overall survival and Cancer-specific survival in prostate cancer patients with bone metastases: a population-based study.
Li B, Xing J, Wang Z, Gong Z, Wang Z, Xu A
BMC Urol. 2023; 23(1):200.
PMID: 38049755
PMC: 10696723.
DOI: 10.1186/s12894-023-01372-w.
Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors.
Gulati R, Nyame Y, Lange J, Shoag J, Tsodikov A, Etzioni R
J Natl Cancer Inst Monogr. 2023; 2023(62):212-218.
PMID: 37947332
PMC: 10637024.
DOI: 10.1093/jncimonographs/lgad018.
Awareness of prostate cancer and its associated factors among male patients attending care in the urology unit at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
Gebru T, Mekonnen H, Getahun N, Meseret F, Masrie A, Mandefro M
BMJ Open. 2023; 13(8):e073602.
PMID: 37553199
PMC: 10414060.
DOI: 10.1136/bmjopen-2023-073602.
Racial/ethnic disparities in the distribution and effect of type and number of high-risk criteria on mortality in prostate cancer patients treated with radiotherapy.
Chierigo F, Flammia R, Sorce G, Hoeh B, Hohenhorst L, Panunzio A
Arab J Urol. 2023; 21(3):135-141.
PMID: 37521449
PMC: 10373609.
DOI: 10.1080/2090598X.2022.2148867.
A nomogram to predict the absence of clinically significant prostate cancer in males with negative MRI.
Kaneko M, Fujihara A, Iwata T, Ramacciotti L, Palmer S, Oishi M
Int Braz J Urol. 2023; 50(3):319-334.
PMID: 37450770
PMC: 11152327.
DOI: 10.1590/S1677-5538.IBJU.2024.0084.
Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer.
Creighton C, Zhang F, Zhang Y, Castro P, Hu R, Islam M
Epigenetics. 2023; 18(1):2180585.
PMID: 37279148
PMC: 9980641.
DOI: 10.1080/15592294.2023.2180585.
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.
Wei J, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R
J Urol. 2023; 210(1):46-53.
PMID: 37096582
PMC: 11060750.
DOI: 10.1097/JU.0000000000003491.
Development and validation of a prognostic nomogram for neuroendocrine prostate cancer, based on the SEER database.
Chen S, Xiong K, Shi J, Yao S, Wang G, Qian K
Front Surg. 2023; 10:1110040.
PMID: 36969760
PMC: 10036588.
DOI: 10.3389/fsurg.2023.1110040.
Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients.
Stevens C, Hightower A, Buxbaum S, Falzarano S, Rhie S
Front Oncol. 2023; 13:1079037.
PMID: 36937425
PMC: 10018228.
DOI: 10.3389/fonc.2023.1079037.
Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry.
Koelker M, Labban M, Frego N, Meyer C, Salomon G, Lipsitz S
World J Urol. 2023; 41(5):1309-1315.
PMID: 36930254
PMC: 10506077.
DOI: 10.1007/s00345-023-04354-7.
Serum Androgen Metabolites Correlate with Clinical Variables in African and European American Men with Localized, Therapy Naïve Prostate Cancer.
Ramakrishnan S, Kittles R, Huss W, Wang J, Attwood K, Woloszynska A
Metabolites. 2023; 13(2).
PMID: 36837903
PMC: 9962438.
DOI: 10.3390/metabo13020284.
Impact of Immune Cells in the Tumor Microenvironment of Prostate Cancer Metastasis.
Messex J, Liou G
Life (Basel). 2023; 13(2).
PMID: 36836690
PMC: 9967893.
DOI: 10.3390/life13020333.
Racism Does Not Cause Prostate Cancer, It Causes Prostate Cancer Death.
Vickers A, Mahal B, Ogunwobi O
J Clin Oncol. 2023; 41(12):2151-2154.
PMID: 36693227
PMC: 10448930.
DOI: 10.1200/JCO.22.02203.
Nomograms predict survival benefits of radical prostatectomy and chemotherapy for prostate cancer with bone metastases: A SEER-based study.
Sun D, Lin A, Sun Z, Yang S, Sun Y, Chen A
Front Oncol. 2022; 12:1020898.
PMID: 36561516
PMC: 9764338.
DOI: 10.3389/fonc.2022.1020898.
